Alkermes Plc remained in negative territory for the whole trading session even after winning an approval from FDA on third attempt and also released schedule for an upcoming earnings for Q3 of fiscal 2012 on Thursday, Feb. 2, 2012.

While three other declining stocks involved in drug delivery business included Elan Corporation, plc (ADR) (NYSE:ELN) faced a drop of 0.83% after announcing for ASCEND study to evaluate the effectiveness of TYSABRI for SPMS, Columbia Laboratories Inc. (NASDAQ:CBRX) fell 0.82% and Valeant Pharmaceuticals (NYSE:VRX) edged down 0.10%.

Out of 15 stocks belong to drug delivery category 7 showed a fall, 2 remained unchanged and 6 achieved to end in positive.

Alkermes Plc (NASDAQ:ALKS) kicked off the last session at an opening price of $19.04 and gained as much as to reach $19.27 but later by the trade end stock slid -0.93% to $19.10.

On the other hand, its trade volume of 721,659 shares was lower than average trading capacity of 897,519 shares. The company’s week performance emerged as +5.99%, 1 year performance moved at +43.61%, and year-to-date performance appeared positive with +10.02% while a month-performance after last trade close went up at +8.03%.

The stock price volatility was 3.06% for a week and 2.98% for a month as well as price volatility’s Average True Range for 14 days was 0.56 and its beta remained 0.79.

ALKS generated revenue of $228.97 billion in the following twelve months and earned -$59.96 million. The Company showed a negative -26.19% in the net profit margin and its operating margin which remained -22.34%. Company’s annual sales growth for the past five years was 2.30%.

The liquidity measure in recent quarter results of the company was recorded +3.94 as current ratio and on the other side the debt to equity ratio was 0.49 while long-term debt to equity ratio remained 0.49. ALKS had a cash of $1.66 per share and a book value per share as $7.01in the most recent quarter.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. galaxystocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://galaxystocks.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold galaxystocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.